(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 18, 2026 (GLOBE NEWSWIRE) -- "RNAi Drug Delivery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global RNAi drug delivery market, valued at US$1.1 billion in 2025, is projected to reach US$4.1 billion by 2032, expanding at a compound annual growth rate of 20.7%. Growth is being supported by advances in delivery technologies, expanding RNA interference therapeutic pipelines, rising investment in precision medicine and increasing demand for treatments targeting chronic, genetic and rare diseases.
RNAi Drug Delivery Market Trends and Growth Drivers
Effective delivery remains central to the clinical and commercial development of RNAi therapeutics. Small interfering RNA is susceptible to nuclease degradation and rapid renal clearance, while its physicochemical properties restrict cellular membrane penetration. Delivery platforms must therefore protect therapeutic payloads, facilitate cellular uptake and endosomal escape, improve tissue specificity and limit off-target activity.
Lipid nanoparticles, polymer-based carriers and conjugation technologies such as N-acetylgalactosamine-siRNA are among the most important delivery modalities. Lipid nanoparticles have demonstrated significant value in hepatic targeting and systemic administration, while polymeric carriers provide structural tunability and controlled-release capabilities. Extracellular vesicles, aptamer-based systems and hybrid lipid-polymer platforms are also attracting research interest because of their potential to improve biodistribution and reduce immunogenicity.
Innovation in ionizable lipids continues to improve RNAi encapsulation, biocompatibility and intracellular release. The clinical validation of lipid nanoparticle delivery, including its use in patisiran, has strengthened investment across the RNAi drug development ecosystem. Polyethyleneimine, poly(lactic-co-glycolic acid), dendrimers, pH-responsive polymers and stimuli-sensitive carriers are also being evaluated for optimized release profiles and reduced systemic toxicity.
Organ- and cell-specific delivery is expected to determine the next phase of market expansion. The liver remains the leading target because of its vascular architecture and compatibility with nanoparticle accumulation. GalNAc conjugation, which uses the asialoglycoprotein receptor pathway in hepatocytes, has enabled targeted subcutaneous administration for hepatic indications.
Beyond the liver, research is advancing delivery to the brain, lungs, eyes and tumors. Investigational approaches include ligand-targeted nanoparticles, extracellular vesicles, focused ultrasound with microbubbles, aerosolized formulations, biodegradable implants and hydrogel systems. Oncology applications remain complex because tumor heterogeneity and immune barriers require platforms capable of selective accumulation, controlled release and low immunogenicity.
Market Outlook and Commercial Opportunities
The RNAi drug delivery market is benefiting from increased biopharmaceutical research and development, expanding late-stage clinical pipelines and improvements in high-throughput screening and bioinformatics. Demand for personalized medicine and minimally invasive administration routes, including subcutaneous, pulmonary and intranasal delivery, is accelerating platform innovation.
Commercial validation of approved RNAi therapies has also strengthened investor confidence in biotechnology companies developing delivery systems and therapeutic candidates. Regulatory pathways supporting rare-disease treatments, including expedited review programs and orphan-drug designations, may further advance selected pipelines. Reimbursement developments in North America and Europe are expected to influence patient access and commercial adoption.
Report Scope
The report analyzes the global RNAi drug delivery market by value in U.S. dollars and provides forecasts from 2025 through 2032.
Technology: Nanoparticle drug delivery, pulmonary drug delivery, nucleic acid drug delivery and aptamer drug delivery. Application: Infectious diseases, cardiology, oncology, neurology, ophthalmology, urology, metabolic disorders and other applications. Geographic coverage: United States, Canada, Japan, China, Europe, Asia-Pacific, Latin America, the Middle East and Africa, with analysis of major national markets.
Key RNAi Drug Delivery Market Insights
The nanoparticle drug delivery segment is forecast to reach US$2.1 billion by 2032, advancing at a CAGR of 23.3%. The pulmonary drug delivery segment is projected to expand at a CAGR of 17.9% during the analysis period. The U.S. RNAi drug delivery market was valued at US$302.2 million in 2025. China is forecast to grow at a CAGR of 27.0% and reach US$991.5 million by 2032. Japan, Canada, Germany and other Asia-Pacific markets are expected to contribute to global growth through expanding research activity, therapeutic development and healthcare investment.
Strategic Value of the Report
Independent annual market estimates and forecasts from 2025 to 2032. Analysis of major technologies, therapeutic applications and geographic markets. Assessment of market drivers, constraints, emerging opportunities and competitive dynamics. Regional and segment-level insights designed to support investment, product development and market-entry decisions. Company intelligence covering established pharmaceutical groups and RNAi-focused biotechnology businesses. Complimentary report updates for one year.
Companies Featured in the RNAi Drug Delivery Market Report
Featured companies include Alnylam Pharmaceuticals, Aro Biotherapeutics, Arrowhead Pharmaceuticals, AstraZeneca, BioNTech SE, Dicerna Pharmaceuticals, DTx Pharma, GlaxoSmithKline, Ionis Pharmaceuticals, Moderna, Novartis, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Sarepta Therapeutics, Silence Therapeutics, Sirnaomics and Switch Therapeutics.
Domain Expert Insights
The report incorporates perspectives from domain experts across industry, enterprise and academia, adding strategic context to conventional market research. The report tracks early market signals emerging from expert discussions, corporate activity, clinical development, conference sessions, executive presentations and regulatory developments before they are fully represented in traditional secondary sources.
Its intelligence base includes validated corporate disclosures, annual reports, institutional publications, conference proceedings, panel discussions, technical blogs and other market-relevant sources. These inputs are synthesized to identify the technologies, therapeutic areas, companies and regional developments most likely to influence the future direction of the global RNAi drug delivery market.
Competitive analysis extends beyond a single global market share measure. Where relevant, the report evaluates market structures across major regions, recognizing that company positioning, adoption patterns, regulatory conditions and technology preferences can vary materially by geography. This approach provides a more practical view of the competitive environment and the strategic opportunities emerging through 2032.
Key Attributes
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment